ArticleRheumatology international2025
Profile of patients with axial spondyloarthritis in Latin America: first report from the ESPALDA-PANLAR registry.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regional patterns of advanced therapy use and unmet disease control in axial spondyloarthritis across Latin America: a report from the ESPALDA-PANLAR registry.Clinical rheumatology · 2026Article
- Clinical phenotype, MRI inflammatory involvement, and treatment patterns in HLA-B27 positive and negative axial spondyloarthritis: a Saudi MRI-based cohort study.BMC rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite increasing recognition of axial spondyloarthritis (axSpA) in Latin America, regional data remain scarce. This study aims to describe the clinical, laboratory, and imaging features of axSpA in Latin America using data from the ESPALDA-PANLAR registry. A cross-sectional analysis was conducted using baseline data from the ESPALDA registry, which includes patients with axSpA across seven Latin American countries. Demographic, clinical, laboratory, and imaging data were collected. Patients were stratified by sex, HLA-B27 status, and radiographic classification. Multivariable logistic regression was performed to identify independent associations. A total of 220 patients were included (56% male), with a mean age of 46 years and median diagnostic delay of 93 months (IQR: 13-122). HLA-B27 was positive in 60% of patients, and 62% met radiographic axSpA classification criteria. In multivariable analysis, radiographic axSpA was independently associated with male sex (OR 4.22; 95% CI 1.53-11.59), SI joint erosions on MRI (OR 3.98; 95% CI 1.45-10.90), and longer diagnostic delay (OR 1.01 per month; 95% CI 1.00-1.01). HLA-B27 positivity was associated with bone marrow edema on MRI (OR 2.81; 95% CI 1.50-5.26) and inversely with psoriasis (OR 0.14; 95% CI 0.06-0.33). This first report from the ESPALDA registry highlights distinctive features of axSpA in Latin America, including lower HLA-B27 prevalence and remarkably diagnostic delay. These findings underscore the need for earlier recognition and regionally adapted strategies for diagnosis and management.
Indexed as
Identifiers
40956329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.